Sarah Patricia Blagden

20PUBLICATIONS
94CO-AUTHORS
Molecular targetsHaematological tumoursCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 23, 2026
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

|May 02, 2026
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

|Jul 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Kenneth Sooi, Tuan Zea Tan, Jae-Weon Kim

|Jul 06, 2025
Precision Prevention Studies: A Targeted Approach to Cancer Prevention.

Sarah P Blagden, Kevin W Dodd, Karen Brown

|Jan 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.

Jia Liu, Max Farrow, Lesley Seymour

|Feb 02, 2024
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Miriam Dixon-Zegeye, Rachel Shaw, Linda Collins

Pageof 4

Frequent Collaborators

4 joint publications

Rebecca Kristeleit

3 joint publications

Ruth Plummer

3 joint publications

Debashis Sarker

2 joint publications

Razelle Kurzrock